このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Sino Biopharmaceutical バランスシートの健全性
財務の健全性 基準チェック /56
Sino Biopharmaceuticalの総株主資本はCN¥38.2B 、総負債はCN¥12.3Bで、負債比率は32.3%となります。総資産と総負債はそれぞれCN¥63.6BとCN¥25.4Bです。 Sino Biopharmaceuticalの EBIT はCN¥5.4Bで、利息カバレッジ比率-46.8です。現金および短期投資はCN¥14.1Bです。
主要情報
22.6%
負債資本比率
CN¥9.51b
負債
| インタレスト・カバレッジ・レシオ | -22.2x |
| 現金 | CN¥13.18b |
| エクイティ | CN¥42.12b |
| 負債合計 | CN¥24.58b |
| 総資産 | CN¥66.70b |
財務の健全性に関する最新情報
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
Sep 02
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Recent updates
Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
Sep 02Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?
Jul 12Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly
May 21Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings
Apr 21What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates
Apr 03Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 20Sino Biopharmaceutical Limited's (HKG:1177) Shares May Have Run Too Fast Too Soon
Dec 18Does Sino Biopharmaceutical (HKG:1177) Have A Healthy Balance Sheet?
Dec 02Sino Biopharmaceutical Limited (HKG:1177) Shares Could Be 41% Below Their Intrinsic Value Estimate
Nov 17We Think Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt With Ease
Aug 30Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 50% Undervaluation?
May 26Sino Biopharmaceutical (HKG:1177) Has A Rock Solid Balance Sheet
Apr 20Is Sino Biopharmaceutical Limited (HKG:1177) Trading At A 38% Discount?
Feb 09Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 41% Undervaluation?
Nov 11Sino Biopharmaceutical (HKG:1177) Seems To Use Debt Quite Sensibly
Oct 24Is There An Opportunity With Sino Biopharmaceutical Limited's (HKG:1177) 46% Undervaluation?
Jul 08Is Sino Biopharmaceutical (HKG:1177) Using Too Much Debt?
Apr 28財務状況分析
短期負債: 1177の 短期資産 ( CN¥23.8B ) が 短期負債 ( CN¥22.6B ) を超えています。
長期負債: 1177の短期資産 ( CN¥23.8B ) が 長期負債 ( CN¥2.8B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: 1177総負債よりも多くの現金を保有しています。
負債の削減: 1177の負債対資本比率は、過去 5 年間で9.1%から32.3%に増加しました。
債務返済能力: 1177の負債は 営業キャッシュフロー によって 十分にカバー されています ( 49.1% )。
インタレストカバレッジ: 1177支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。